COVID-19

Scientific Publications

PMID: 21283743
Title: Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative KAVI Kenya
Abstract: With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research into HIV vaccines and drugs. Sub-Saharan African countries--worst affected by the HIV pandemic--have participated in the conduct of clinical trials for HIV vaccines. In Kenya, the Kenya AIDS Vaccine Initiative (KAVI) at the University of Nairobi has conducted HIV vaccine clinical trials since 2001.
Date: 1970-08-20
Year: 2011
Journal: PLoS ONE
PMID Author: Omosa-Manyonyi GS, Jaoko W, Anzala O, Ogutu H, Wakasiaka S, Malogo R, Nyange J, Njuguna P, Ndinya-Achola J, Bhatt K, Farah B, Oyaro M, Schmidt C, Priddy F, Fast P
IAVI Topics: IAVI Clinical Trial
IAVI Keywords: IAVI V001

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative KAVI Kenya

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya. PLoS ONE 2011;6(1):e14580 doi: 10.1371/journal.pone.0014580

Media Contacts

Africa

Ethel Makila
+254 71 904 3142
EMakila@iavi.org 

 

Europe

Hester Kuipers
+31 20 521 0343
HKuipers@iavi.org 

 

India

Devi Leena Bose
+91 11 4737 6031
DLeena@iavi.org 

 

North America

Rose Catlos
+1 212 847 1049
RCatlos@iavi.org